AN2 Therapeutics reports Q1 2025 net loss of $10.6M; cash runway extended to 2028

AN2 Therapeutics, Inc.

2025-Q1 EPS reported -$0.35

Net loss of $10.6M vs $16.6M in Q1 2024; R&D expenses down to $7.7M from $14.7M.
Cash and investments of $78.5M at March 31, 2025; operating runway now projected into 2028.
Initiated Phase 1 first-in-human study of AN2-502998 for chronic Chagas disease; expected completion in H2 2025.
Plans to initiate Phase 2 study of epetraborole in melioidosis; advancing epetraborole for NTM lung disease non-dilutive.
Oncology pipeline advancing; first compound(s) expected to enter development in 2025 within current cash runway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.